miRagen Therapeutics Inc., formerly Signal Genetics, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of micro-ribonucleic acid (RNA)-targeted therapies. Its lead product candidates, MRG-106 and MRG-201, are in Phase I clinical trials. Its therapeutic areas of focus include cancer, pathologic fibrosis, neuro-inflammatory and cardiovascular diseases. Its clinical product candidate for the treatment of certain cancers, MRG-106, is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. The Company's clinical product candidate for the treatment of pathological fibrosis, MRG-201, is a replacement for miR-29, which is found at abnormally low levels in a range of pathological fibrotic conditions, including cardiac, renal, hepatic and pulmonary fibrosis, as well as systemic sclerosis. In addition to its clinical programs, it is developing a pipeline of pre-clinical product candidates.